These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 17016152)

  • 41. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer disease.
    Bartha R; Smith M; Rupsingh R; Rylett J; Wells JL; Borrie MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):786-93. PubMed ID: 18252268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antipsychotic effects on auditory sensory gating in schizophrenia patients.
    Sánchez-Morla EM; Santos JL; Aparicio A; García-Jiménez MA; Villanueva C; Martínez-Vizcaíno V; Arango C
    Eur Neuropsychopharmacol; 2009 Dec; 19(12):905-9. PubMed ID: 19833483
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impaired P50 sensory gating in post-traumatic stress disorder secondary to urban violence.
    Ghisolfi ES; Margis R; Becker J; Zanardo AP; Strimitzer IM; Lara DR
    Int J Psychophysiol; 2004 Feb; 51(3):209-14. PubMed ID: 14962572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nicotine and sensory memory in Alzheimer's disease: an event-related potential study.
    Engeland C; Mahoney C; Mohr E; Ilivitsky V; Knott V
    Brain Cogn; 2002 Jul; 49(2):232-4. PubMed ID: 15259398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia.
    Paci C; Gobbato R; Carboni T; Sanguigni S; Santone A; Curatola L
    Neurol Sci; 2006 Feb; 26(6):435-7. PubMed ID: 16601937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice.
    Cachard-Chastel M; Devers S; Sicsic S; Langlois M; Lezoualc'h F; Gardier AM; Belzung C
    Behav Brain Res; 2008 Mar; 187(2):455-61. PubMed ID: 18061284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduced short latency afferent inhibition in patients with Down syndrome and Alzheimer-type dementia.
    Nardone R; Marth R; Ausserer H; Bratti A; Tezzon F
    Clin Neurophysiol; 2006 Oct; 117(10):2204-10. PubMed ID: 16931146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
    Jones RW; Kivipelto M; Feldman H; Sparks L; Doody R; Waters DD; Hey-Hadavi J; Breazna A; Schindler RJ; Ramos H;
    Alzheimers Dement; 2008 Mar; 4(2):145-53. PubMed ID: 18631958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early and late auditory sensory gating: moderating influences from schizotypal personality, tobacco smoking status, and acute smoking.
    Wan L; Crawford HJ; Boutros N
    Psychiatry Res; 2007 May; 151(1-2):11-20. PubMed ID: 17292483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease.
    Foldi NS; White RE; Schaefer LA
    Int J Geriatr Psychiatry; 2005 May; 20(5):485-8. PubMed ID: 15852461
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
    Campanozzi MD; Casali E; Neviani F; Martini E; Neri M
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():91-6. PubMed ID: 17317439
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Behavioural and ERP indices of response inhibition during a Stop-signal task in children with two subtypes of Attention-Deficit Hyperactivity Disorder.
    Johnstone SJ; Barry RJ; Clarke AR
    Int J Psychophysiol; 2007 Oct; 66(1):37-47. PubMed ID: 17604142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 54. P50 sensory gating deficit in children with centrotemporal spikes and sharp waves in the EEG.
    Fiedler BJ; Debus OM; Neubauer BA; Kienle M; Kurlemann G
    Neurosci Lett; 2006 Jan; 393(2-3):206-10. PubMed ID: 16246492
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study.
    Tamimi I; Ojea T; Sanchez-Siles JM; Rojas F; Martin I; Gormaz I; Perez A; Dawid-Milner MS; Mendez L; Tamimi F
    J Bone Miner Res; 2012 Jul; 27(7):1518-27. PubMed ID: 22467182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evoked and event related coherence of Alzheimer patients manifest differentiation of sensory-cognitive networks.
    Başar E; Güntekin B; Tülay E; Yener GG
    Brain Res; 2010 Oct; 1357():79-90. PubMed ID: 20732310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reliability of P50 auditory sensory gating measures in infants during active sleep.
    Hunter SK; Corral N; Ponicsan H; Ross RG
    Neuroreport; 2008 Jan; 19(1):79-82. PubMed ID: 18281897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. P50 and acoustic startle gating are not related in healthy participants.
    Brenner CA; Edwards CR; Carroll CA; Kieffaber PD; Hetrick WP
    Psychophysiology; 2004 Sep; 41(5):702-8. PubMed ID: 15318876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and gender in the P50 paradigm.
    Brinkman MJ; Stauder JE
    Clin Neurophysiol; 2007 Jul; 118(7):1517-24. PubMed ID: 17509936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [P50 component of auditory evoked potentials in persons with schizophrenia and their first degree relatives].
    Wegrzyn J; Wciórka J
    Psychiatr Pol; 2004; 38(3):395-408. PubMed ID: 15199650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.